Kylixa (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

The combination blocks the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), preventing ovulation. Drospirenone also has anti‑mineralocorticoid activity, while ethinylestradiol stabilises the endometrium. Together they thicken cervical mucus and alter the uterine lining, making fertilisation and implantation unlikely.

The dosing regimen for Kylixa is determined by the prescribing healthcare professional. Typically, the product is taken as one tablet daily at the same time for three weeks followed by a placebo or hormone‑free interval, but the exact schedule and any adjustments are individualized by the prescriber.

Kylixa is intended for use only when a woman is not pregnant. If pregnancy occurs, the product should be discontinued and alternative contraception considered. Limited data are available for breastfeeding; generally, combined oral contraceptives are not recommended during the early postpartum period without medical guidance.

To place an order, submit an enquiry on the Kylixa product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kylixa contains drospirenone, which has anti‑mineralocorticoid properties that may reduce water retention compared with older progestogens such as levonorgestrel. Its efficacy in preventing pregnancy is comparable to other combined pills, while the side‑effect profile may differ slightly, offering potential benefits for patients concerned about bloating or hypertension.

Kylixa tablets should be stored at ambient temperature, below 25 °C, in their original blister pack to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Kylixa is taken orally, usually once daily at the same time each day. The typical regimen consists of 21 active tablets followed by a 7‑day hormone‑free interval, during which withdrawal bleeding occurs. Patients should swallow the tablet whole with water and should not skip doses without consulting their prescriber.

The most serious risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction and severe hypertension, which can be life‑threatening. These events are more likely in women who smoke, are over 35, have a history of clotting disorders, or have certain cardiovascular conditions. Immediate medical attention is required if symptoms arise.

Kylixa is contraindicated in women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, or are smokers over 35 years of age. It should also be avoided in patients with known hypersensitivity to drospirenone, ethinylestradiol or any tablet excipients.